Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease

被引:88
作者
Takahide, Kikuchi
Parker, Pablo M.
Wu, Michael
Hwang, William Y. K.
Carpenter, Paul A.
Moravec, Carina
Stehr, Barbara
Martin, Pauly F.
Rosenthal, Perry
Forman, Stephen F.
Flowers, Mary E. D.
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[2] City Hope Natl Med Ctr, Seattle, WA USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Singapore Gen Hosp, Singapore 0316, Singapore
[5] Harvard Med Sch, Boston Fdn Sight, Boston, MA USA
关键词
graft-versus-host disease; keratoconjunctivitis sicca; allogeneic hematopoietic cell transplantation;
D O I
10.1016/j.bbmt.2007.05.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Keratoconjunctivitis sicca (KCS) occurs in 40%-60% of patients with chronic graft-versus-host-disease (cGVHD) after allogeneic hematopoietic cell transplantation. Although immunosuppressive therapy is the primary treatment of chronic GVHD, ocular symptoms require measures to improve ocular lubrication, decrease inflammation, and maintain mucosal integrity. The liquid corneal bandage provided by a fluid-ventilated, gas-permeable scleral lens (SL) has been effective in mitigating symptoms and resurfacing corneal erosions in patients with KCS related to causes other than cGVHD. We report outcomes in 9 consecutive patients referred for SL fitting for cGVHD-related severe KCS that was refractory to standard treatments. All patients reported improvement of ocular symptoms and reduced the use of topical lubricants after SL fitting resulting from decreased evaporation. No serious adverse events or infections attributable to the SL occurred. The median Ocular Surface Disease Index improved from 81 (75-100) to 21 (6-52) within 2 weeks after SL fitting, and was 12 (2-53) at the time of last contact, 1-23 months (median, 8.0) after SL fitting. Disability related to KCS resolved in 7 patients after SL fitting. The use of SL appears to be safe and effective in patients with severe cGVHD-related KCS refractory to conventional therapies. (c) 2007 American Society for Blood and Marrow Transplantation
引用
收藏
页码:1016 / 1021
页数:6
相关论文
共 12 条
[1]  
CALISSENDORFF B, 1989, BONE MARROW TRANSPL, V4, P675
[2]   Ancillary therapy and supportive care of chronic graft-versus-host disease:: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease:: V.: Ancillary Therapy and Supportive Care Working Group report [J].
Couriel, D ;
Carpenter, PA ;
Cutler, C ;
Bolaños-Meade, J ;
Treister, NS ;
Gea-Banacloche, J ;
Shaughnessy, P ;
Hymes, S ;
Kim, S ;
Wayne, AS ;
Chien, JW ;
Neumann, J ;
Mitchell, S ;
Syrjala, K ;
Moravec, CK ;
Abramovitz, L ;
Liebermann, J ;
Berger, A ;
Gerber, L ;
Schubert, M ;
Filipovich, AH ;
Weisdorf, D ;
Schubert, MM ;
Shulman, H ;
Schultz, K ;
Mittelman, B ;
Pavletic, S ;
Vogelsang, GB ;
Martin, PJ ;
Lee, SJ ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (04) :375-396
[3]   Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial [J].
Flowers, MED ;
Parker, PM ;
Johnston, LJ ;
Matos, AVB ;
Storer, B ;
Bensinger, WI ;
Storb, R ;
Appelbaum, FR ;
Forman, SJ ;
Blume, KG ;
Martin, PJ .
BLOOD, 2002, 100 (02) :415-419
[4]  
Hart D E, 1994, J Am Optom Assoc, V65, P517
[5]   The use of topical cyclosporin A in ocular graft-versus-host-disease [J].
Kiang, E ;
Tesavibul, N ;
Yee, R ;
Kellaway, J ;
Przepiorka, D .
BONE MARROW TRANSPLANTATION, 1998, 22 (02) :147-151
[6]   Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease [J].
Ogawa, Y ;
Okamoto, S ;
Mori, T ;
Yamada, M ;
Mashima, Y ;
Watanabe, R ;
Kuwana, M ;
Tsubota, K ;
Ikeda, Y ;
Oguchi, Y .
BONE MARROW TRANSPLANTATION, 2003, 31 (07) :579-583
[7]   Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids [J].
Ogawa, Y ;
Okamoto, S ;
Kuwana, M ;
Mori, T ;
Watanabe, R ;
Nakajima, T ;
Yamada, M ;
Mashima, Y ;
Tsubota, K ;
Oguchi, Y .
CORNEA, 2001, 20 (04) :430-434
[8]  
Rosenthal Perry, 2005, Eye Contact Lens, V31, P130, DOI 10.1097/01.ICL.0000152492.98553.8D
[9]   A GAS-PERMEABLE SCLERAL CONTACT-LENS FOR VISUAL REHABILITATION [J].
SCHEIN, OD ;
ROSENTHAL, P ;
DUCHARME, C .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1990, 109 (03) :318-322
[10]   Reliability and validity of the ocular surface disease index [J].
Schiffman, RM ;
Christianson, MD ;
Jacobsen, G ;
Hirsch, JD ;
Reis, BL .
ARCHIVES OF OPHTHALMOLOGY, 2000, 118 (05) :615-621